Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Truist analyst Jailendra Singh raised the firm’s price target on Hims & Hers to $39 from $24 and keeps a Hold rating on the shares after ...